Juan Miguel Cejalvo Andújar: Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women
Juan Miguel Cejalvo Andújar, Medical Oncologist at Clinical Hospital of Valencia, posted on LinkedIn about recent paper he and colleagues co-authored:
“We’ve just published a new study on HR+/HER2− breast cancer in very young women (≤35 years)
Our findings reveal key age-related differences in this subtype:
• Greater tumor heterogeneity and proliferation.
• Strong immune activation and higher immune cell infiltration.
• Lower hormone receptor mRNA expression.
• Potential for immunotherapy due to “hot” tumor features.
• Better predicted response to chemotherapy, but less to endocrine therapy.
This work supports the need for personalized treatment strategies for young patients.”
“Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women.”
Authors: Iris Garrido-Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres-Ruiz, Anna Ágreda-Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó-Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023